Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
The response rate, with five complete responses, exceeds known responses to standard-of-care chemotherapy in heavily pre-treated folate receptor alpha-high patients. A US FDA filing is on track for early 2022.
PI3K-delta inhibitors have often suffered from safety and tolerability issues, but Phase II data show higher efficacy and lower discontinuation rates for zandelisib than others in the class.
Lengo’s preclinical LNG-451, along with Blueprint’s BLU-945 and BLU-701, could create a portfolio of therapies covering 97% of non-small cell lung cancer cases involving EGFR exon mutations.
In a new landmark, Chinese firm BeiGene has posted greater quarterly sales of its cancer drug Brukinsa in the US than in China for the first time. Meanwhile, a growing number of innovative products developed in China are on the cusp of expansion into overseas markets.
Regeneron is investing heavily to advance five vaccine programs with Nykode Therapeutics, the Norwegian company formerly known as Vaccibody.
The approval of Fyarro marks the first for advanced malignant PEComa, a rare cancer that affects only 100-300 people in the US; it's also the first launch for Aadi Biosciences.
From BTK inhibitors in multiple sclerosis to candidates aiding cancer cell death, Merck KGaA is focusing on its first-in-class pipeline which it expects to make a significant impact from 2025.
Early clinical results for AFM13 combined with NK cells showed high response rates without serious toxicities, and the data could have readthrough to the company’s EGFR-targeted therapy.
Deal Snapshot: The two firms will seek to co-develop and co-commercialize targeted small molecule cancer therapies that they identify at the preclinical stage.
Japanese firm and key discoverer of immuno-oncology protein reach settlement of patent-related dispute that includes formation of new academic research fund.
Gilead is licensing two anti-TIGIT candidates and a pair of adenosine pathway-targeted drugs. The firms will study various IO combo regimens, possibly including Gilead drugs like Trodelvy.
Janssen global oncology therapeutic area head Peter Lebowitz talked to Scrip about the company's next big ambitions in lung, bladder and prostate cancer.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.